Amgen, Inc. (AMGN) Expected to Earn FY2018 Earnings of $14.17 Per Share

Share on StockTwits

Amgen, Inc. (NASDAQ:AMGN) – Investment analysts at Jefferies Financial Group upped their FY2018 earnings estimates for Amgen in a research report issued on Wednesday, October 31st. Jefferies Financial Group analyst M. Yee now expects that the medical research company will post earnings per share of $14.17 for the year, up from their previous forecast of $14.11. Jefferies Financial Group currently has a “Buy” rating and a $220.00 target price on the stock. Jefferies Financial Group also issued estimates for Amgen’s Q1 2019 earnings at $3.81 EPS, Q2 2019 earnings at $3.63 EPS, Q3 2019 earnings at $3.38 EPS, Q4 2019 earnings at $3.48 EPS and FY2019 earnings at $14.31 EPS.

Several other analysts have also recently commented on the company. Cann restated a “buy” rating and set a $224.00 target price on shares of Amgen in a report on Monday, October 1st. Royal Bank of Canada restated a “neutral” rating and set a $193.00 target price on shares of Amgen in a report on Monday, September 10th. Oppenheimer restated a “buy” rating and set a $224.00 target price on shares of Amgen in a report on Tuesday, August 28th. Goldman Sachs Group reaffirmed a “buy” rating and set a $229.00 price target on shares of Amgen in a research note on Friday, October 12th. Finally, Mizuho reaffirmed a “buy” rating and set a $200.00 price target on shares of Amgen in a research note on Friday, July 27th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $204.37.

Shares of AMGN stock opened at $192.79 on Thursday. The company has a current ratio of 3.39, a quick ratio of 3.12 and a debt-to-equity ratio of 2.03. The firm has a market cap of $122.39 billion, a PE ratio of 15.33, a price-to-earnings-growth ratio of 1.83 and a beta of 1.40. Amgen has a 52 week low of $163.31 and a 52 week high of $210.19.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, October 30th. The medical research company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.45 by $0.24. The company had revenue of $5.90 billion for the quarter, compared to analysts’ expectations of $5.78 billion. Amgen had a return on equity of 51.05% and a net margin of 9.44%. The business’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.27 earnings per share.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 7th. Stockholders of record on Friday, November 16th will be paid a dividend of $1.32 per share. This represents a $5.28 annualized dividend and a dividend yield of 2.74%. The ex-dividend date is Thursday, November 15th. Amgen’s dividend payout ratio (DPR) is presently 41.97%.

Several institutional investors and hedge funds have recently modified their holdings of AMGN. Principal Financial Group Inc. lifted its stake in Amgen by 1.4% in the first quarter. Principal Financial Group Inc. now owns 1,187,759 shares of the medical research company’s stock valued at $202,489,000 after buying an additional 15,948 shares during the period. Cardinal Capital Management Inc. lifted its stake in Amgen by 22.2% in the second quarter. Cardinal Capital Management Inc. now owns 82,900 shares of the medical research company’s stock valued at $15,303,000 after buying an additional 15,035 shares during the period. First Financial Bank Trust Division lifted its stake in Amgen by 47.4% in the second quarter. First Financial Bank Trust Division now owns 2,102 shares of the medical research company’s stock valued at $388,000 after buying an additional 676 shares during the period. Gulf International Bank UK Ltd lifted its stake in Amgen by 2.3% in the second quarter. Gulf International Bank UK Ltd now owns 217,679 shares of the medical research company’s stock valued at $40,181,000 after buying an additional 4,851 shares during the period. Finally, Abner Herrman & Brock LLC lifted its stake in Amgen by 1.5% in the second quarter. Abner Herrman & Brock LLC now owns 52,841 shares of the medical research company’s stock valued at $9,754,000 after buying an additional 802 shares during the period. 82.37% of the stock is currently owned by institutional investors and hedge funds.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Recommended Story: Book Value Per Share – BVPS

Earnings History and Estimates for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply